<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01521169</url>
  </required_header>
  <id_info>
    <org_study_id>NU332</org_study_id>
    <nct_id>NCT01521169</nct_id>
  </id_info>
  <brief_title>Long-term Effectiveness Study on Cholesterol-reducing Activity</brief_title>
  <official_title>Clinical Study for Evaluating the Plasma Cholesterol-reducing Activity of a Plant Sterol-enriched Yoghurt Drink - Effectiveness and Long-term Safety Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danone Japan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Danone Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effect of consumption of a drinkable low fat&#xD;
      fermented milk enriched with 0,8g or 1,6g of plant sterols on reducing plasma cholesterol&#xD;
      (LDL-cholesterol) concentration during 12 weeks of product consumption.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">138</enrollment>
  <condition>Normal and Mild Hypercholesterolemic Subjects</condition>
  <arm_group>
    <arm_group_label>1 = Tested product dose 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2 = Tested product dose 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3 = Control product</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>1 - low-fat dairy fermented product (drinkable) enriched with plant sterols (0,8g /day equivalent as free sterols).</intervention_name>
    <description>1 = Intervention with test product 1 (0,8g of plant sterol/day)</description>
    <arm_group_label>1 = Tested product dose 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>2 - low-fat dairy fermented product (drinkable) enriched with plant sterols (1,6g /day equivalent as free sterols).</intervention_name>
    <description>2 = Intervention with test product 2 (1,6g of plant sterol/day)</description>
    <arm_group_label>2 = Tested product dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>3 - low-fat dairy fermented product (drinkable) without plant sterols.</intervention_name>
    <description>3 = Intervention 3 (1 control product/day)</description>
    <arm_group_label>3 = Control product</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject with total cholesterol plasma level between 200 mg/dL to 240 mg/dL; and&#xD;
             LDL-cholesterol between 120 mg/dL to 160 mg/dL.&#xD;
&#xD;
          2. Subject aged from 20 to 65 years (bounds included)&#xD;
&#xD;
          3. Subject with BMI between 19 - 30 kg/m² (bounds included)&#xD;
&#xD;
          4. Subject with triglycerides under 400 mg/dL (4.6 mmol/L)&#xD;
&#xD;
          5. Non diabetic subjects (BS≤125 mg/dL)&#xD;
&#xD;
          6. Non hypertensive subjects (SBP&lt;140mmHg and DBP&lt;90 mmHg)&#xD;
&#xD;
          7. Subject accepting to follow the dietary recommendations advisable for&#xD;
             hypercholesterolemic&#xD;
&#xD;
          8. Subject agreeing not to consume any other plant sterol supplements or excess plant&#xD;
             sterol during the study period&#xD;
&#xD;
          9. Subject, upon briefing of the content of the present study, fully understanding and&#xD;
             agreeing to its objective; and being able to personally sign a written informed&#xD;
             consent and subject having signed the written consent to take part in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject currently involved in a clinical trial.&#xD;
&#xD;
          2. Subject taking any dislipademia treatment (statins,ezetimibe, niacin, omega-3 FA,&#xD;
             fibrates)&#xD;
&#xD;
          3. Subject having blood sample of 200 ml or more taken (e.g., donated blood) within 1&#xD;
             month, or 400 ml or more within 3 months of the start of the present study.&#xD;
&#xD;
          4. For female subject: pregnancy or intention to be pregnant during the study.&#xD;
&#xD;
          5. For female subject: breast feeding.&#xD;
&#xD;
          6. Subject presenting known allergy or history of hypersensitivity to plant sterols or&#xD;
             dairy products.&#xD;
&#xD;
          7. Subject having lactose intolerance.&#xD;
&#xD;
          8. Subjects having sitosterolemia&#xD;
&#xD;
          9. Diabetic subject (Type I and type II)&#xD;
&#xD;
         10. Subject with heavy alcohol intake (&gt;60g/day)&#xD;
&#xD;
         11. Subject receiving systemic treatment or topical treatment likely to interfere with&#xD;
             evaluation of the study parameters&#xD;
&#xD;
         12. Subject receiving a transplant or under immunosuppressor treatment&#xD;
&#xD;
         13. Subject receiving treatment for serious liver, renal, cardio-vascular, respiratory,&#xD;
             endocrine, or metabolic disorders.&#xD;
&#xD;
         14. Subject having cardiovascular history or cardiovascular events (e.g.myocardial&#xD;
             infarction, angina pectoris, surgical or endocoronary intervention, stroke, inferior&#xD;
             member arteriopathy, etc.) during the last 6 months&#xD;
&#xD;
         15. Subject deemed unsuitable by the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Senrichuo Ekimae Clinic - Senri Life Science Center 13F</name>
      <address>
        <city>Osaka</city>
        <zip>560-0082</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>January 26, 2012</study_first_submitted>
  <study_first_submitted_qc>January 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2012</study_first_posted>
  <last_update_submitted>October 26, 2016</last_update_submitted>
  <last_update_submitted_qc>October 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Plant sterol - Hypercholesterolemia - Diet - Dairy</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

